As previously reported, Wedbush analyst raised his price target for Alteryx to Outperform from Neutral as his customer and industry checks make him bullish on the company's ability to maintain its revenue momentum with relatively minimal deceleration and high net expansion rates for its industry-leading self-service data analytics platform. His contacts note Alteryx is successfully penetrating the G2K and expanding renewal sizes with well-honed sales execution, especially in the Global 2000. This success is translating into strong dollar-based net expansion and sustained revenue growth, he adds. The analyst also raised his price target on the shares to $135 from $123.

New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).